Omega Therapeutics , Inc. (NASDAQ:OMGA), a biotechnology firm with a market capitalization of $13.45 million, has secured debtor-in-possession (DIP) financing following its voluntary Chapter 11 ...

Investment trusts have a number of tricks up their sleeves that mean they can boost their dividend payouts. This is what to ...

Four members of the East Knox FFA competed in the State FFA Agricultural Biotechnology Career Development Event at the Ohio Department of Agriculture on Jan. 24. The local team placed 16th in the ...

Now with 95% of the data analysed, the company is confident of drawing more definitive conclusions. The upshot? The company is definitively “closing the book” on its lead – and sole – drug candidate ...

The news seemed to signal a shifting tide in the biotech industry, which in recent years has been hit by layoffs and declining venture funding. But multiple life science leaders say it’s not so ...

Canada’s Foreign Minister Melanie Joly warned that proposed U.S. tariffs could force America to rely on Venezuelan oil imports, as tensions escalate ahead of President Donald Trump‘s planned ...

Drug development and commercialization leads to tremendous advances in medicine and improvements to everyday life, but it often comes at a cost. Delayed clinical trials, regulatory approvals, and ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

Oath Keepers founder Stewart Rhodes and Proud Boy Tom Vournas were among those released following President Trump’s pardon. Photo: Roberto Schmidt/AFP/Getty Images Some of the highest profile ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...